JP2023025187A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023025187A5 JP2023025187A5 JP2022193805A JP2022193805A JP2023025187A5 JP 2023025187 A5 JP2023025187 A5 JP 2023025187A5 JP 2022193805 A JP2022193805 A JP 2022193805A JP 2022193805 A JP2022193805 A JP 2022193805A JP 2023025187 A5 JP2023025187 A5 JP 2023025187A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- genetically engineered
- domain
- antigen
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024200383A JP2025026930A (ja) | 2017-03-31 | 2024-11-18 | Ｔ細胞受容体シグナル伝達を阻害または調節することによって、ｔ細胞枯渇を処置する方法 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762479930P | 2017-03-31 | 2017-03-31 | |
| US62/479,930 | 2017-03-31 | ||
| JP2019553214A JP7249287B2 (ja) | 2017-03-31 | 2018-03-30 | Ｔ細胞受容体シグナル伝達を阻害または調節することによって、ｔ細胞枯渇を処置する方法 |
| PCT/US2018/025459 WO2018183888A2 (en) | 2017-03-31 | 2018-03-30 | Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019553214A Division JP7249287B2 (ja) | 2017-03-31 | 2018-03-30 | Ｔ細胞受容体シグナル伝達を阻害または調節することによって、ｔ細胞枯渇を処置する方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024200383A Division JP2025026930A (ja) | 2017-03-31 | 2024-11-18 | Ｔ細胞受容体シグナル伝達を阻害または調節することによって、ｔ細胞枯渇を処置する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023025187A JP2023025187A (ja) | 2023-02-21 |
| JP2023025187A5 true JP2023025187A5 (https=) | 2023-04-13 |
| JP7674328B2 JP7674328B2 (ja) | 2025-05-09 |
Family
ID=63677091
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019553214A Active JP7249287B2 (ja) | 2017-03-31 | 2018-03-30 | Ｔ細胞受容体シグナル伝達を阻害または調節することによって、ｔ細胞枯渇を処置する方法 |
| JP2019553220A Active JP7278961B2 (ja) | 2017-03-31 | 2018-03-30 | Ｔ細胞受容体のシグナル伝達を阻害するまたは調節することによってｔ細胞の疲弊を治療する方法 |
| JP2022193805A Active JP7674328B2 (ja) | 2017-03-31 | 2022-12-02 | Ｔ細胞受容体シグナル伝達を阻害または調節することによって、ｔ細胞枯渇を処置する方法 |
| JP2023011257A Pending JP2023055805A (ja) | 2017-03-31 | 2023-01-27 | Ｔ細胞受容体のシグナル伝達を阻害するまたは調節することによってｔ細胞の疲弊を治療する方法 |
| JP2024123405A Pending JP2024153812A (ja) | 2017-03-31 | 2024-07-30 | Ｔ細胞受容体のシグナル伝達を阻害するまたは調節することによってｔ細胞の疲弊を治療する方法 |
| JP2024200383A Pending JP2025026930A (ja) | 2017-03-31 | 2024-11-18 | Ｔ細胞受容体シグナル伝達を阻害または調節することによって、ｔ細胞枯渇を処置する方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019553214A Active JP7249287B2 (ja) | 2017-03-31 | 2018-03-30 | Ｔ細胞受容体シグナル伝達を阻害または調節することによって、ｔ細胞枯渇を処置する方法 |
| JP2019553220A Active JP7278961B2 (ja) | 2017-03-31 | 2018-03-30 | Ｔ細胞受容体のシグナル伝達を阻害するまたは調節することによってｔ細胞の疲弊を治療する方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023011257A Pending JP2023055805A (ja) | 2017-03-31 | 2023-01-27 | Ｔ細胞受容体のシグナル伝達を阻害するまたは調節することによってｔ細胞の疲弊を治療する方法 |
| JP2024123405A Pending JP2024153812A (ja) | 2017-03-31 | 2024-07-30 | Ｔ細胞受容体のシグナル伝達を阻害するまたは調節することによってｔ細胞の疲弊を治療する方法 |
| JP2024200383A Pending JP2025026930A (ja) | 2017-03-31 | 2024-11-18 | Ｔ細胞受容体シグナル伝達を阻害または調節することによって、ｔ細胞枯渇を処置する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20200101108A1 (https=) |
| EP (2) | EP3600323A4 (https=) |
| JP (6) | JP7249287B2 (https=) |
| CN (3) | CN118161496A (https=) |
| AU (3) | AU2018243571B2 (https=) |
| CA (2) | CA3057505A1 (https=) |
| WO (2) | WO2018183842A1 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111699001A (zh) * | 2017-12-07 | 2020-09-22 | 尤利乌斯·马克西米利安维尔茨堡大学 | 达沙替尼和其他酪氨酸激酶抑制剂对基因修饰的嵌合抗原受体t细胞的功能的控制和调节 |
| WO2020092650A1 (en) * | 2018-10-30 | 2020-05-07 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for modulating t cell exhaustion |
| CA3117978A1 (en) * | 2018-11-08 | 2020-05-14 | Juno Therapeutics, Inc. | Methods and combinations for treatment and t cell modulation |
| CN120174005A (zh) | 2019-02-13 | 2025-06-20 | 比姆医疗股份有限公司 | 具有用于修饰靶标序列中核碱基的腺苷脱氨酶碱基编辑器的经修饰的免疫细胞 |
| EP3931216A4 (en) * | 2019-03-01 | 2023-04-19 | National University of Singapore | MANIPULATED IMMUNE CELLS |
| CN110157680A (zh) * | 2019-05-08 | 2019-08-23 | 浙江大学 | 提高嵌合抗原受体t细胞疗效和作用持久性的细胞培养方法 |
| EP4008347B1 (en) * | 2019-08-01 | 2025-04-30 | Mie University | GD2-BINDING MOLECULE |
| EP4034138A4 (en) | 2019-09-27 | 2024-07-31 | Beam Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIQUID CANCERS |
| GB202000934D0 (en) * | 2020-01-22 | 2020-03-04 | Ucl Business Ltd | Engineered immune cells |
| CA3158133A1 (en) | 2020-04-28 | 2021-11-04 | Lyell Immunopharma, Inc. | Methods for culturing cells |
| EP4159843A4 (en) * | 2020-05-29 | 2024-07-31 | Shanghai Juncell Therapeutics Co., Ltd. | MEDIUM FOR SEEDING CELLS OF TUMOR INFILTRATING LYMPHOCYTES AND ITS APPLICATION |
| MX2022015764A (es) * | 2020-06-19 | 2023-01-19 | Chugai Pharmaceutical Co Ltd | Molecula de union al antigeno anti-celulas t para usarse en combinacion con un inhibidor de angiogenesis. |
| KR20230074146A (ko) * | 2020-09-24 | 2023-05-26 | 에프. 호프만-라 로슈 아게 | T 세포 이중특이성 항체 관련 역효과의 예방 또는 완화 |
| CA3196831A1 (en) | 2020-09-25 | 2022-03-31 | Beam Therapeutics Inc. | Fratricide resistant modified immune cells and methods of using the same |
| JP2023549079A (ja) * | 2020-10-30 | 2023-11-22 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | 二重標的化キメラ抗原受容体 |
| WO2022210487A1 (ja) * | 2021-03-29 | 2022-10-06 | タカラバイオ株式会社 | 抗原に特異的な受容体を発現する免疫細胞の製造方法 |
| EP4071248A1 (en) | 2021-04-07 | 2022-10-12 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Means and methods for enhancing receptor-targeted gene transfer |
| US20240238419A1 (en) * | 2021-05-07 | 2024-07-18 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Method for constitutive malt1 protease activation |
| CN113533729B (zh) * | 2021-06-15 | 2024-09-06 | 北京大学人民医院 | 一种鉴定aml患者骨髓中nk细胞耗竭的研究方法及其应用 |
| JP2024525727A (ja) | 2021-07-14 | 2024-07-12 | ２セブンティ バイオ インコーポレイテッド | 抗体由来の結合ドメインに融合した操作されたｔ細胞受容体 |
| CN115677861B (zh) * | 2021-07-29 | 2026-03-06 | 上海科技大学 | 一种泛素偶联修饰的嵌合抗原受体及免疫细胞 |
| IL312204A (en) | 2021-10-28 | 2024-06-01 | Lyell Immunopharma Inc | Methods for culturing cells expressing ror1-binding protein |
| IL312201A (en) | 2021-10-28 | 2024-06-01 | Lyell Immunopharma Inc | Methods for culturing cells expressing c-jun |
| CA3255500A1 (en) | 2022-04-08 | 2023-10-12 | Regeneron Pharmaceuticals, Inc. | MULTI-PART RECEIVERS AND SIGNALING COMPLEXES |
| AU2023292081A1 (en) * | 2022-06-13 | 2025-01-09 | The Regents Of The University Of California | Improved glycan-dependent chimeric antigen receptor cells |
| GB202218144D0 (en) * | 2022-12-02 | 2023-01-18 | Univ Oxford Innovation Ltd | Product |
| CN116121196B (zh) * | 2022-12-23 | 2025-07-22 | 广州安捷生物医学技术有限公司 | 一种调控car-t细胞的方法与应用 |
| WO2025221871A1 (en) * | 2024-04-16 | 2025-10-23 | The Trustees Of Columbia University In The City Of New York | Expansion, propagation, and modulation of immune cell subsets by peptides |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2210812C (en) | 1995-01-16 | 2009-09-01 | Nicholas Manolios | T-cell affecting peptides |
| US20050070478A1 (en) | 1996-06-11 | 2005-03-31 | Northern Sydney Area Health Services | T cell antigen receptor peptides |
| US20050113564A1 (en) | 2003-11-05 | 2005-05-26 | St. Jude Children's Research Hospital | Chimeric receptors with 4-1BB stimulatory signaling domain |
| GB0523954D0 (en) | 2005-11-24 | 2006-01-04 | Ucb Celltech | Bioassays |
| US9334330B2 (en) | 2006-10-10 | 2016-05-10 | Universite De Nantes | Use of monoclonal antibodies specific to the O-acetylated form of GD2 ganglioside for the treatment of certain cancers |
| US8173792B2 (en) | 2007-02-09 | 2012-05-08 | The Board Of Trustees Of The Leland Stanford Junior University | Method for regulating protein function in cells using synthetic small molecules |
| EP2664916B1 (en) | 2007-04-02 | 2017-02-08 | Acoustic Cytometry Systems, Inc. | Method for manipulating a fluid medium within a flow cell using acoustic focusing |
| WO2012033885A1 (en) | 2010-09-08 | 2012-03-15 | Baylor College Of Medicine | Immunotherapy of cancer using genetically engineered gd2-specific t cells |
| US9845362B2 (en) | 2010-10-08 | 2017-12-19 | The University Of North Carolina At Charlotte | Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| CA2832540C (en) | 2011-04-08 | 2020-09-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer |
| PL3892295T3 (pl) | 2011-05-24 | 2023-07-24 | BioNTech SE | Zindywidualizowane szczepionki przeciwnowotworowe |
| ES2654060T3 (es) | 2011-10-20 | 2018-02-12 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Receptores de antígenos quiméricos anti-CD22 |
| CA2857687C (en) * | 2011-12-02 | 2019-07-09 | Stillwater Mining Company | Quantitative precious metals recovery in the presence of interfering metals, salts, and ions |
| RU2766608C2 (ru) | 2012-04-11 | 2022-03-15 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток |
| WO2014055771A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Human alpha-folate receptor chimeric antigen receptor |
| DK2956175T3 (da) | 2013-02-15 | 2017-11-27 | Univ California | Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf |
| JP6647868B2 (ja) | 2013-02-20 | 2020-02-14 | ノバルティス アーゲー | ヒト化抗ＥＧＦＲｖＩＩＩキメラ抗原受容体を用いたがんの処置 |
| US9446105B2 (en) | 2013-03-15 | 2016-09-20 | The Trustees Of The University Of Pennsylvania | Chimeric antigen receptor specific for folate receptor β |
| US9790282B2 (en) | 2013-03-25 | 2017-10-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-CD276 polypeptides, proteins, and chimeric antigen receptors |
| EP3783098A1 (en) | 2013-05-14 | 2021-02-24 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| US9636340B2 (en) * | 2013-11-12 | 2017-05-02 | Ayyappan K. Rajasekaran | Kinase inhibitors |
| GB201403972D0 (en) | 2014-03-06 | 2014-04-23 | Ucl Business Plc | Chimeric antigen receptor |
| WO2015179801A1 (en) * | 2014-05-23 | 2015-11-26 | University Of Florida Research Foundation, Inc. | Car based immunotherapy |
| EP3169363A4 (en) | 2014-07-16 | 2018-02-21 | F. Hoffmann-La Roche AG | Methods of treating cancer using tigit inhibitors and anti-cancer agents |
| TWI719942B (zh) | 2014-07-21 | 2021-03-01 | 瑞士商諾華公司 | 使用ｃｄ３３嵌合抗原受體治療癌症 |
| ES2878449T3 (es) * | 2014-07-24 | 2021-11-18 | 2Seventy Bio Inc | Receptores antigénicos quiméricos de BCMA |
| MX2017002205A (es) | 2014-08-19 | 2017-08-21 | Novartis Ag | Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer. |
| WO2016061368A1 (en) | 2014-10-15 | 2016-04-21 | The Children's Hospital Of Philadelphia | Compositions and methods for treating b-lymphoid malignancies |
| GB201500319D0 (en) * | 2015-01-09 | 2015-02-25 | Agency Science Tech & Res | Anti-PD-L1 antibodies |
| WO2016134284A1 (en) * | 2015-02-19 | 2016-08-25 | University Of Florida Research Foundation, Inc. | Chimeric antigen receptors and uses thereof |
| US9777064B2 (en) | 2015-03-17 | 2017-10-03 | Chimera Bioengineering, Inc. | Smart CAR devices, DE CAR polypeptides, side CARs and uses thereof |
| GB201514328D0 (en) | 2015-08-12 | 2015-09-23 | Sigmoid Pharma Ltd | Compositions |
| JP7653759B2 (ja) | 2016-01-20 | 2025-03-31 | フェイト セラピューティクス，インコーポレイテッド | 養子免疫療法における免疫細胞調節のための組成物および方法 |
| KR20230148844A (ko) * | 2016-03-29 | 2023-10-25 | 유니버시티 오브 써던 캘리포니아 | 암을 표적하는 키메라 항원 수용체 |
| CN109715808A (zh) * | 2016-04-15 | 2019-05-03 | 诺华股份有限公司 | 用于选择性蛋白质表达的组合物和方法 |
| EP3548049A4 (en) | 2016-12-05 | 2020-07-22 | Fate Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR MODULATION OF IMMUNE CELLS IN ADOPTIVE IMMUNOTHERAPIES |
| CN111699001A (zh) | 2017-12-07 | 2020-09-22 | 尤利乌斯·马克西米利安维尔茨堡大学 | 达沙替尼和其他酪氨酸激酶抑制剂对基因修饰的嵌合抗原受体t细胞的功能的控制和调节 |
| WO2020092650A1 (en) * | 2018-10-30 | 2020-05-07 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for modulating t cell exhaustion |
-
2018
- 2018-03-30 US US16/499,762 patent/US20200101108A1/en active Pending
- 2018-03-30 CN CN202410272411.XA patent/CN118161496A/zh active Pending
- 2018-03-30 CA CA3057505A patent/CA3057505A1/en active Pending
- 2018-03-30 WO PCT/US2018/025394 patent/WO2018183842A1/en not_active Ceased
- 2018-03-30 AU AU2018243571A patent/AU2018243571B2/en active Active
- 2018-03-30 JP JP2019553214A patent/JP7249287B2/ja active Active
- 2018-03-30 EP EP18775932.9A patent/EP3600323A4/en active Pending
- 2018-03-30 JP JP2019553220A patent/JP7278961B2/ja active Active
- 2018-03-30 CA CA3057372A patent/CA3057372A1/en active Pending
- 2018-03-30 CN CN201880029045.8A patent/CN110603044B/zh active Active
- 2018-03-30 AU AU2018243664A patent/AU2018243664B2/en active Active
- 2018-03-30 EP EP18777667.9A patent/EP3600357A4/en active Pending
- 2018-03-30 WO PCT/US2018/025459 patent/WO2018183888A2/en not_active Ceased
- 2018-03-30 CN CN201880028993.XA patent/CN110582280B/zh active Active
- 2018-03-30 US US16/499,760 patent/US11938153B2/en active Active
-
2022
- 2022-12-02 JP JP2022193805A patent/JP7674328B2/ja active Active
-
2023
- 2023-01-27 JP JP2023011257A patent/JP2023055805A/ja active Pending
-
2024
- 2024-02-21 US US18/583,096 patent/US20240293461A1/en active Pending
- 2024-06-07 AU AU2024203919A patent/AU2024203919A1/en active Pending
- 2024-07-30 JP JP2024123405A patent/JP2024153812A/ja active Pending
- 2024-11-18 JP JP2024200383A patent/JP2025026930A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023025187A5 (https=) | ||
| JP2020515259A5 (https=) | ||
| JP2017522893A5 (https=) | ||
| Kober et al. | The capacity of the TNF family members 4‐1BBL, OX40L, CD70, GITRL, CD30L and LIGHT to costimulate human T cells | |
| JP2025186319A5 (https=) | ||
| US12059436B2 (en) | BCMA-CAR-T cells | |
| JP2023515211A5 (https=) | ||
| Finnefrock et al. | PD-1 blockade in rhesus macaques: impact on chronic infection and prophylactic vaccination | |
| AU2026202096A1 (en) | Methods and systems for performing a patient-specific immunotherapy procedure with chain-of-custody and chain-of-identity biological sample tracking | |
| JP2019511212A5 (https=) | ||
| AU2018388997B2 (en) | Compositions and methods for treating HIV/AIDS with immunotherapy | |
| JP2021518108A5 (https=) | ||
| JP2018504143A5 (https=) | ||
| JP2020513754A5 (https=) | ||
| JP2006521783A5 (https=) | ||
| EP3471770A1 (en) | Tunable chimeric antigen receptors | |
| JP2018533371A5 (https=) | ||
| JP2019513370A5 (https=) | ||
| JP2022512882A5 (https=) | ||
| JP2018501794A (ja) | 細胞 | |
| JP2018526033A5 (https=) | ||
| JP2018537076A5 (https=) | ||
| RU2017110044A (ru) | Антитела и химерные антигенные рецепторы, специфичные к cd19 | |
| CN110035773A (zh) | 新型抗ctla4抗体 | |
| JP2016514462A5 (https=) |